	US 12,264,200 B2
	Antibody variable domains targeting the NKG2D receptor
Gregory P. Chang, Medford, MA (US); Ann F. Cheung, Lincoln, MA (US); Asya Grinberg, Lexington, MA (US); William Haney, Wayland, MA (US); Bradley M. Lunde, Lebanon, NH (US); and Bianka Prinz, Lebanon, NH (US)
Assigned to Dragonfly Therapeutics, Inc., Waltham, MA (US)
Filed by Dragonfly Therapeutics, Inc., Waltham, MA (US)
Filed on Nov. 3, 2023, as Appl. No. 18/501,427.
Application 18/501,427 is a division of application No. 16/967,216, granted, now 11,884,733, previously published as PCT/US2019/017330, filed on Feb. 8, 2019.
Claims priority of provisional application 62/716,259, filed on Aug. 8, 2018.
Claims priority of provisional application 62/628,161, filed on Feb. 8, 2018.
Prior Publication US 2024/0076385 A1, Mar. 7, 2024
Int. Cl. C07K 16/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12P 21/08 (2006.01); C07K 1/00 (2006.01)

CPC C07K 16/2851 (2013.01) [C07K 16/2803 (2013.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

18 Claims

1. An antigen-binding site that binds NKG2D, comprising:

an antibody heavy chain variable domain comprising a complementarity-determining region 1 (CDR1) amino acid sequence of SEQ ID NO: 48, a complementarity-determining region 2 (CDR2) amino acid sequence of SEQ ID NO: 30, and a complementarity-determining region 3 (CDR3) amino acid sequence of SEQ ID NO: 71; and

an antibody light chain variable domain comprising a CDR1 amino acid sequence of SEQ ID NO: 32, a CDR2 amino acid sequence of SEQ ID NO: 33, and a CDR3 amino acid sequence of SEQ ID NO: 34.